Publication: Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group
Issued Date
2012-08-01
Resource Type
ISSN
10292403
10428194
10428194
Other identifier(s)
2-s2.0-84864245939
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia and Lymphoma. Vol.53, No.8 (2012), 1515-1524
Suggested Citation
Seok Jin Kim, Joon Ho Moon, Hawk Kim, Jin Seok Kim, Yu Yan Hwang, Tanin Intragumtornchai, Surapol Issaragrisil, Jae Yong Kwak, Je Jung Lee, Jong Ho Won, Arry Harryanto Reksodiputro, Soon Thye Lim, Ann Lii Cheng, Won Seog Kim, Yok Lam Kwong Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group. Leukemia and Lymphoma. Vol.53, No.8 (2012), 1515-1524. doi:10.3109/10428194.2012.659735 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/13658
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group
Other Contributor(s)
SungKyunKwan University, School of Medicine
Kyungpook National University Hospital
University of Ulsan, College of Medicine
Yonsei University College of Medicine
Queen Mary Hospital Hong Kong
Chulalongkorn University
Mahidol University
Chonbuk National University, School of Medicine
Chonnam National University, College of Medicine
Soonchunhyang University, College of Medicine
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Centre, Singapore
National Taiwan University Hospital
Kyungpook National University Hospital
University of Ulsan, College of Medicine
Yonsei University College of Medicine
Queen Mary Hospital Hong Kong
Chulalongkorn University
Mahidol University
Chonbuk National University, School of Medicine
Chonnam National University, College of Medicine
Soonchunhyang University, College of Medicine
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Centre, Singapore
National Taiwan University Hospital
Abstract
This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of frontline (n = 48) or salvage (n = 90) treatment, and as a part of the conditioning regimen for allogeneic stem cell transplant (n = 44). Reactivation of cytomegalovirus (66/182) and varicella zoster virus (25/182), and fungal infection (31/182) including invasive pulmonary aspergillosis, were the most common infectious complications in this retrospective analysis. Thus, we recommend routine prophylaxis with valganciclovir and itraconazole, especially when alemtuzumab is used in the conditioning regimen for allogeneic stem cell transplant. Pneumocystis jirovecii pneumonia (PJP) was found in four patients (3%, 4/122) receiving alemtuzumab as conditioning for stem cell transplant or salvage treatment. Three cases of hepatitis B virus reactivation were found in antigen-negative patients, and 16 cases of tuberculosis were observed. Infection is the major complication of alemtuzumab therapy, and these infectious complications are potentially severe and life-threatening. Based on our retrospective analysis, we have constructed a guideline for antimicrobial prophylaxis in Asian patients receiving alemtuzumab therapy. © 2012 Informa UK, Ltd.